| bexarotene 1 % Topical Gel |
PSN |
| bexarotene 1 % Topical Gel |
SY |
| bexarotene 1 % Topical Gel |
PSN |
| bexarotene 1 % Topical Gel |
SY |
| bexarotene 1 % Topical Gel |
PSN |
| bexarotene 1 % Topical Gel |
SY |
| bexarotene 1 % Topical Gel |
PSN |
| bexarotene 1 % Topical Gel |
SY |
| bexarotene 75 MG Oral Capsule |
PSN |
| bexarotene 75 MG Oral Capsule |
SCD |
| bexarotene 75 MG Oral Capsule |
PSN |
| bexarotene 75 MG Oral Capsule |
SCD |
| bexarotene 75 MG Oral Capsule |
PSN |
| bexarotene 75 MG Oral Capsule |
SCD |
| bexarotene 75 MG Oral Capsule |
PSN |
| bexarotene 75 MG Oral Capsule |
SCD |
| bexarotene 75 MG Oral Capsule |
PSN |
| bexarotene 75 MG Oral Capsule |
SCD |
| bexarotene 75 MG Oral Capsule |
PSN |
| bexarotene 75 MG Oral Capsule |
SCD |
| bexarotene 75 MG Oral Capsule |
PSN |
| bexarotene 75 MG Oral Capsule |
SCD |
| bexarotene 75 MG Oral Capsule |
PSN |
| bexarotene 75 MG Oral Capsule |
SCD |
| bexarotene 75 MG Oral Capsule |
PSN |
| bexarotene 75 MG Oral Capsule |
SCD |
| bexarotene 75 MG Oral Capsule [Targretin] |
SBD |
| Bexsero (meningococcal group B vaccine 0.1 MG/ML / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen 0.1 MG/ML / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen 0.1 MG/ML / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle 0.05 MG/ML) per 0.5 ML Prefilled Syringe |
SY |
| Bexsero (meningococcal group B vaccine 50 MCG / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen 50 MCG / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen 50 MCG / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle 25 MCG) per 0.5 ML Prefilled Syringe |
SY |
| Bexsero Meningococcal Group B Vaccine 0.5 ML Prefilled Syringe |
SY |